

This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

News

- We are currently advertising for a Project Assistant to continue the work on a sustainable plan to monitor reporting compliance.
- We have launched [Statewide Gateway Integration!](#)

Upcoming Activities

- The Delegate Audit will be conducted in March.
- The 2023 Awareness and Feedback Questionnaire will launch in March/April. An announcement will be made through AWARxE and posted to users' dashboards.

Registration

Portal

Number of licensed Nurses: 1,843
Prescriptive Authority: 1,443
Number with DEA Registrations: 1,364
Number of PDMP Designations: 1,327
Directly Dispensing Controlled Substances: 75

AWARxE (PDMP)

Number registered with the PDMP: 1,158
Does not include anyone registered with an IHS, VA, or Military user role.

Review

Federally Scheduled II – III controlled substances, over a three-day supply (emergency, surgical and oncology specialties are omitted). The system does not capture treatment codes and is therefore not able to account for prescription(s) not reviewed due to some of the exemptions in AS 17.30.200(k)(4)(A).

Q1 2022: 45%
Q4 2022: 42%

Recommendations

- Promote increased reviewing. Mandatory review applies to non-refillable federally scheduled II – III controlled substances over a three-day supply (for further exemptions see AS 17.30.200(k)).
- Encourage the use of authorized delegates.
- Remind providers who are directly dispensing to report daily, including zero reports.
- Sign up for [Statewide Gateway Integration](#).